BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Coramitug readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Coramitug\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07448623-634@assetmemo.bio
DTSTAMP:20261121T004523Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Coramitug: Phase 1 readout est. (NCT07448623)
DESCRIPTION:Coramitug\, phase 1.\nStudy: A Research Study to Look at the Di
 stribution and Effects of Coramitug on Amyloid Deposits in Heart Tissue Us
 ing PET/CT Imaging in People With ATTR Amyloidosis.\nEstimated primary com
 pletion: 30 May 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /coramitug#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07448623
URL:https://assetmemo.bio/drug/coramitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06260709-634@assetmemo.bio
DTSTAMP:20261121T004523Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Coramitug: Phase 2 readout est. (NCT06260709)
DESCRIPTION:Coramitug\, phase 2\, Heart Failure.\nStudy: A Research Study t
 o Look at Long-term Treatment With a Medicine Called NNC6019-0001 for Peop
 le Who Have Heart Failure Due to Transthyretin Amyloidosis\nEstimated prim
 ary completion: 29 February 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/coramitug#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06260709
URL:https://assetmemo.bio/drug/coramitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07207811-634@assetmemo.bio
DTSTAMP:20261121T004523Z
DTSTART;VALUE=DATE:20290629
DTEND;VALUE=DATE:20290630
SUMMARY:Coramitug: Phase 3 readout est. (NCT07207811)
DESCRIPTION:Coramitug\, phase 3\, Heart Failure.\nStudy: CLEOPATTRA: A Rese
 arch Study to Look at the Effects of Treatment With a Medicine Called Cora
 mitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amy
 loid (ATTR) Amyloidosis\nEstimated primary completion: 29 June 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/coramitug#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07207811
URL:https://assetmemo.bio/drug/coramitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
